GlassScriptPhysician profile
Peter Thomas Geleskie
NPI 1609840131
$19,527.77
in general payments reported to CMS, 2019-2025
49 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,687 · 2020: $2,904 · 2021: $3,619 · 2022: $2,927 · 2023: $2,417 · 2024: $2,385 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,391.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,038.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,510.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,403.37 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $1,135.05 | 2019-2025 | |
| Lilly USA, LLC | $1,121.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,022.35 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Gilead Sciences, INC. | $920.90 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $807.07 | 2019-2025 | |
| Abbvie INC. | $649.63 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $584.28 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $541.53 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $508.36 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $442.75 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.31 | 2019-2024 | Jardiance, Synjardy |
| Nestle Healthcare Nutrition INC. | $260.02 | 2021-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Geleskie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.